ROCKLAND, Mass.--(BUSINESS WIRE)--BioSphere Medical, Inc. (NASDAQ: BSMD) today announced that more than 40,000 Ob/Gyns and other health care professionals are expected to receive a supplement in the May 2008 issue of OBG Management, which concludes that Ob/Gyns can expect a higher degree of patient loyalty and patient retention by openly and fully discussing all treatment options for symptomatic uterine fibroids, including uterus-sparing, minimally invasive uterine fibroid embolization (UFE). Patient loyalty and retention are proposed to contribute to the long-term growth and profitability of the practice.
